import { LegacyEducationalContent } from '../../../types'

export const drugAllergy: LegacyEducationalContent = {
  id: 'drug-allergy',
  title: 'Drug Allergy',
  specialty: 'allergy-immunology',
  category: 'allergic-conditions',

  levels: {
    1: {
      title: 'Introduction to Drug Allergy',
      description: 'Basic understanding of allergic reactions to medications',
      content: `
# What is Drug Allergy?

A drug allergy occurs when your immune system reacts to a medication as if it were a harmful substance. This can cause various symptoms ranging from mild to severe.

## Common Drug Allergies

### Antibiotics
- Penicillin
- Sulfa drugs
- Cephalosporins

### Pain Relievers
- Aspirin
- Ibuprofen
- Naproxen (NSAIDs)

### Others
- Contrast dye used in imaging tests
- Chemotherapy drugs
- Anti-seizure medications

## Symptoms

### Mild to Moderate
- Skin rash or hives
- Itching
- Fever
- Swelling of face, lips, or tongue

### Severe (Anaphylaxis)
- Difficulty breathing
- Swelling of throat
- Dizziness or fainting
- Rapid heartbeat
- Loss of consciousness

## What to Do

If you suspect a drug allergy:
1. Stop taking the medication
2. Call your doctor immediately
3. For severe symptoms, call 911
4. Keep records of which medications caused reactions

## Prevention

- Tell all healthcare providers about drug allergies
- Wear a medical alert bracelet
- Know the names of medications you're allergic to
- Ask about drug interactions
- Keep an updated medication list
      `
    },

    beginner: {
      title: 'Understanding Drug Allergy',
      description: 'Learn about types, diagnosis, and management of drug allergies',
      content: `
# Understanding Drug Allergy

## Drug Allergy vs. Side Effect

### Drug Allergy
- Immune system reaction
- Can occur with any dose
- Typically develops after first exposure
- Symptoms: rash, itching, anaphylaxis

### Side Effect
- Not immune-mediated
- Dose-dependent
- Known effects of the drug
- Examples: nausea, drowsiness, dry mouth

## Types of Drug Reactions

### Immediate Reactions (IgE-mediated)
- Occur within minutes to 1-2 hours
- Hives, swelling, anaphylaxis
- Penicillin most common cause

### Delayed Reactions
- Occur days to weeks after starting drug
- Various types of rashes
- More common than immediate reactions

### Other Immune Reactions
- Serum sickness (fever, joint pain, rash)
- Drug reaction with eosinophilia (DRESS)
- Stevens-Johnson syndrome (severe)

## Common Drug Allergens

### Beta-Lactam Antibiotics
- Penicillins (most common)
- Cephalosporins (some cross-reactivity)
- Carbapenems, monobactams

### Non-Beta-Lactam Antibiotics
- Sulfonamides (Bactrim, Septra)
- Macrolides (less common)
- Fluoroquinolones (rare)

### NSAIDs and Aspirin
- Can cause respiratory reactions
- Can cause skin reactions
- May be related to enzyme deficiency

### Others
- Contrast media
- Chemotherapy agents
- Biologics
- Vaccines (rare)

## Diagnosis

### Medical History
- Detailed reaction description
- Timing relative to drug administration
- Previous exposures
- Other medications taken

### Testing Options

**Skin Testing**
- Available for some drugs (penicillin, others)
- Prick and intradermal tests
- Performed by allergy specialists
- Negative test often rules out IgE allergy

**Blood Tests**
- Specific IgE for some drugs
- Not available for most medications
- Limited utility

**Drug Challenge**
- Graded dose challenge
- Gold standard for many drugs
- Performed under medical supervision

## Management

### Avoidance
- Know exact drug names
- Inform all healthcare providers
- Wear medical alert identification
- Maintain allergy list

### Desensitization
- When no alternative exists
- Temporary tolerance induction
- Performed in hospital setting
- Must be repeated if drug needed again

### Cross-Reactivity Considerations

**Penicillin and Cephalosporins**
- First-generation: ~10% cross-reactivity
- Later generations: <2% cross-reactivity
- Side chain structure important

**Sulfonamides**
- Sulfa antibiotics vs. non-antibiotic sulfonamides
- Diuretics, diabetes medications
- Usually not cross-reactive

### When Allergy History is Uncertain

**Penicillin Allergy**
- 10% of population reports allergy
- >90% are not truly allergic
- Penicillin skin testing available
- Evaluation important for antibiotic stewardship
      `
    },

    intermediate: {
      title: 'Clinical Management of Drug Allergy',
      description: 'Comprehensive approach to diagnosis and treatment',
      content: `
# Clinical Management of Drug Allergy

## Classification of Drug Reactions

### Type A (Predictable)
- Dose-dependent
- Related to pharmacologic action
- Account for 80% of ADRs
- Examples: renal toxicity from NSAIDs, bleeding from anticoagulants

### Type B (Unpredictable)
- Not dose-dependent
- Immunologic or idiosyncratic
- Account for 15-20% of ADRs
- Include allergic reactions

## Immunologic Mechanisms (Gell and Coombs)

### Type I: IgE-Mediated
- Immediate reactions (minutes-hours)
- Urticaria, anaphylaxis, bronchospasm
- Penicillin, neuromuscular blockers, latex

### Type II: Cytotoxic
- Antibody-mediated cell destruction
- Hemolytic anemia, thrombocytopenia
- Penicillin, quinidine, methyldopa

### Type III: Immune Complex
- Serum sickness-like reactions
- Fever, arthralgias, urticaria
- Serum sickness, serum sickness-like (cefaclor)

### Type IV: Delayed Hypersensitivity
- T-cell mediated (days-weeks)
- Maculopapular rash, contact dermatitis
- Most common drug rash mechanism

## Specific Drug Allergies

### Beta-Lactam Allergy

**Penicillin**
- Most common IgE-mediated drug allergy
- Cross-reactivity: Determined by side chains, not beta-lactam ring
- Skin testing: Pre-pen (PPL), MDM, native penicillin
- Negative predictive value: >97% with skin test + challenge
- Penicillin skin testing major and minor determinants

**Cephalosporins**
- Cross-reactivity with penicillin:
  - First generation: 10%
  - Second/third generation: 2-5%
  - Fourth/fifth generation: <1%
- Side chain similarity determines cross-reactivity
- Direct skin testing with cephalosporin possible

**Graded Challenge Protocol**
- Indicated when: Negative skin test, low-risk history
- Doses: 1%, 10%, 25%, 50%, 100% of therapeutic dose
- Interval: 15-30 minutes
- Performed in medically supervised setting

### Aspirin/NSAID Exacerbated Respiratory Disease (AERD)

**Clinical Triad**
1. Asthma
2. Chronic rhinosinusitis with nasal polyps
3. Respiratory reaction to aspirin/NSAIDs

**Pathophysiology**
- COX-1 inhibition → shunting to leukotriene production
- Overproduction of cysteinyl leukotrienes
- Not IgE-mediated

**Reactions**
- Nasal congestion, bronchospasm
- Occur 30 minutes to 3 hours after ingestion
- Can be life-threatening

**Management**
- Avoid COX-1 inhibitors (aspirin, ibuprofen, naproxen)
- Acetaminophen <1000mg usually tolerated
- COX-2 inhibitors (celecoxib) usually tolerated
- Aspirin desensitization for patients needing aspirin

### Sulfonamide Antibiotic Allergy

**Clinical Features**
- Maculopapular rash (most common)
- Stevens-Johnson syndrome (rare)
- DRESS, serum sickness
- More common in HIV-positive patients

**Cross-Reactivity**
- Among sulfonamide antibiotics
- NOT with non-antibiotic sulfonamides (diuretics, sulfonylureas)
- Lack shared N1 heterocyclic ring

## Severe Cutaneous Adverse Reactions (SCARs)

### Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

**Drugs Implicated**
- Sulfonamides, penicillins, cephalosporins
- Anticonvulsants (carbamazepine, lamotrigine, phenytoin)
- Allopurinol
- NSAIDs (oxicams)

**Clinical Features**
- Flu-like prodrome
- Painful skin, mucosal involvement
- Full-thickness necrosis, epidermal detachment
- <10% BSA: SJS; >30% BSA: TEN

**Diagnosis**
- Clinical + histopathology
- Biopsy: full-thickness necrosis
- Nikolsky sign positive

**Management**
- Immediate drug cessation
- Burn unit care
- Supportive care
- IVIG or cyclosporine (controversial)

### Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

**Features**
- Fever, rash
- Facial edema
- Eosinophilia, atypical lymphocytes
- Organ involvement (liver, kidney, lung)

**Drugs**
- Anticonvulsants, allopurinol, sulfonamides
- Minocycline, vancomycin
- Latency: 2-8 weeks

**Diagnostic Criteria (RegiSCAR)**
- Hospitalization
- Suspected drug reaction
- Acute skin rash
- Fever >38°C
- Eosinophilia >10% or >1500/μL
- Lymphadenopathy
- Involvement of ≥1 internal organ

**Management**
- Drug discontinuation
- Systemic corticosteroids
- Supportive care
- Reactivation of HHV-6, EBV, CMV common

### Acute Generalized Exanthematous Pustulosis (AGEP)

**Features**
- Widespread pustular eruption
- Fever, neutrophilia
- Mucosal involvement uncommon

**Drugs**
- Antibiotics (beta-lactams, macrolides)
- Terbinafine, diltiazem, hydroxychloroquine

**Course**
- Self-limited (peaks 3-4 days)
- Desquamation after pustules resolve
- Fever resolves with eruption

## Diagnostic Testing

### Skin Testing

**Indications**
- IgE-mediated reactions suspected
- Penicillin, neuromuscular blockers, latex
- Chemotherapy agents (platinum-based)

**Methods**
- Skin prick test: Screening
- Intradermal test: If prick negative
- Read at 15-20 minutes (immediate)

**Limitations**
- Not available for most drugs
- Negative doesn't guarantee tolerance
- False positives possible

### In Vitro Testing

**Specific IgE**
- Penicillin (major and minor determinants)
- Limited commercial availability
- Lower sensitivity than skin testing

**Other Tests**
- Lymphocyte transformation test (research)
- Cytokine release assays
- BAT (basophil activation test) - emerging

### Drug Provocation Tests

**Gold Standard**
- Graded challenge to suspected drug
- Distinguishes true allergy from tolerance
- Should be done for low-risk histories

**Protocol Considerations**
- Starting dose: 1/100 to 1/10 of therapeutic
- Multi-step dose escalation
- Observation periods
- Rescue medications available
- ICU vs. ward vs. outpatient based on risk

**Contraindications**
- SJS/TEN, DRESS
- Severe cutaneous reactions
- Organ-threatening reactions
- High-risk reactions

## Management Strategies

### Avoidance

**Identify Cross-Reactive Drugs**
- Beta-lactam cross-reactivity
- Sulfonamide cross-reactivity
- Local anesthetic cross-reactivity (amide vs. ester)

**Alternative Medications**
- Unrelated classes
- Non-immune mechanisms

### Drug Desensitization

**Indications**
- No equally effective/available alternatives
- History of IgE-mediated reaction
- Drug is essential

**Mechanisms**
- Temporary mast cell desensitization
- IgE cross-linking without degranulation
- Mast cell exhaustion

**Protocols**

*Outpatient (low risk)*
- 8-12 step protocol
- 15-30 minutes between doses
- Antihistamine premedication

*Inpatient (high risk)*
- ICU monitoring
- Continuous monitoring
- More gradual protocols

**Maintenance Dosing**
- Daily dosing maintains tolerance
- Interruption may require re-desensitization
- Desensitization does NOT cure allergy

### Graded Challenge vs. Desensitization

**Graded Challenge (Test Dose)**
- Low probability of allergy
- Single procedure
- If tolerated, patient not allergic

**Desensitization**
- High probability of allergy
- Temporary tolerance induction
- Requires ongoing drug exposure
      `
    },

    advanced: {
      title: 'Advanced Drug Allergy Management',
      description: 'Complex presentations and special populations',
      content: `
# Advanced Drug Allergy Management

## Special Populations

### Pregnancy

**Considerations**
- Limited medication options
- Physiologic changes affect drug metabolism
- Fetal considerations
- Rh immune globulin (anti-D): contains trace IgA

**Evaluating Allergies in Pregnancy**
- Careful risk-benefit assessment
- Skin testing generally safe
- Drug challenges in high-risk settings
- Desensitization when needed

### Critical Care Patients

**Challenges**
- Multiple medications
- ICU drug formulary limitations
- Cross-reactivity constraints
- Severity of illness

**Common Issues**
- Neuromuscular blockers (anaphylaxis risk)
- Antibiotics (beta-lactams, vancomycin)
- Contrast media
- Opioids (histamine release vs. true allergy)

### Patients with Multiple Drug Allergies

**Evaluation Approach**
- Detailed reaction histories
- Identify true vs. reported allergies
- Prioritize evaluation of most impactful allergies
- Consider genetic testing (HLA alleles)

**Penicillin Allergy Evaluation**
- High yield (>90% not allergic)
- Antibiotic stewardship
- SPADE study methodology
- Direct challenge in low-risk patients

## Chemotherapy and Biologic Allergy

### Platinum-Based Chemotherapy

**Reactions**
- Carboplatin, cisplatin, oxaliplatin
- IgE-mediated (platinum >7 exposure)
- Type I reactions

**Management**
- Desensitization protocols (standardized)
- Skin testing available (oxaliplatin)
- 4-12 step protocols

### Taxanes

**Reactions**
- Paclitaxel, docetaxel
- Often due to Cremophor EL vehicle
- Not always IgE-mediated

**Management**
- Premedication (H1/H2 blockers, steroids)
- Slower infusion rates
- Desensitization for severe reactions

### Monoclonal Antibodies

**Reactions**
- Infusion-related reactions
- Cytokine release
- Specific IgE-mediated reactions

**Management**
- Premedication
- Slower infusion rates
- Desensitization protocols available
- Switching to alternative agents

### Biologics: Specific Considerations

**Anti-TNF Agents**
- Infliximab, adalimumab, etanercept
- Infusion reactions
- Loss of efficacy over time (immunogenicity)

**Anti-CD20**
- Rituximab
- Severe reactions with high tumor burden
- Premedication standard

**Immune Checkpoint Inhibitors**
- Pembrolizumab, nivolumab, ipilimumab
- Immune-related adverse events (irAEs)
- Not allergic reactions
- Management: steroids, immunosuppression

## Radiocontrast Media

**Types**

**Iodinated Contrast**
- High-osmolar: more reactions
- Low-osmolar: fewer reactions
- Iso-osmolar: lowest reaction rate

**Gadolinium-Based**
- MRI contrast
- NSF risk with renal failure
- Reactions less common than iodinated

**Reactions**
- Immediate (type I-like)
- Delayed (days later)
- Not true IgE-mediated (most)

**Risk Factors**
- Previous reaction
- Asthma, allergies
- Beta-blocker use
- Female gender

**Management**

*Premedication Protocol*
- Prednisone 50mg PO 13, 7, 1 hours before
- Diphenhydramine 50mg PO/IV 1 hour before
- Consider H2 blocker
- Use low-osmolar contrast

*Reactions to Premedication*
- Repeat premedication dose schedule
- Use alternative contrast agents
- Consider desensitization

**Contrast Allergy Testing**
- Skin testing not predictive
- No validated tests
- Clinical history guides management

## Local Anesthetic Allergy

**True Incidence**
- <1% of reported reactions are true allergies
- Most reactions: vasovagal, anxiety, toxicity

**Types**

*Amides*
- Lidocaine, bupivacaine, mepivacaine
- Cross-reactivity: within amides
- Most commonly used

*Esters*
- Benzocaine, tetracaine, procaine
- Metabolized to PABA (allergen)
- Cross-reactivity: within esters

**Evaluation**
- Detailed reaction history
- Skin prick and intradermal testing
- Graded challenge if testing negative
- Preservative allergy possible

**Management**
- True allergy: use alternative class
- Preservative allergy: preservative-free alternative
- Test dosing for unexplained reactions

## Opioid Allergy

**Reactions**
- Histamine release (most common)
- Not true IgE-mediated (usually)
- Codeine, morphine: most histamine release
- Fentanyl, oxycodone: less histamine release

**True IgE-Mediated**
- Rare case reports
- Skin testing not standardized
- Graded challenge for evaluation

**Management**
- Use alternative opioid
- Antihistamine premedication
- Test dose for uncertain cases

## Neuromuscular Blocking Agents (NMBAs)

**Anaphylaxis Risk**
- Most common cause of OR anaphylaxis
- Rocuronium, succinylcholine highest risk
- IgE-mediated reactions

**Cross-Reactivity**
- Based on quaternary ammonium ion
- Benzylisoquinoliniums: less cross-reactivity
- Aminosteroids: more cross-reactivity

**Evaluation**
- Skin testing available
- Serum tryptase during reaction
- Baseline tryptase comparison

**Management**
- Preoperative identification
- Use alternative NMBA
- Desensitization rarely needed

## Antibiotic Allergy in Complex Patients

### Cystic Fibrosis

**Challenges**
- Multiple antibiotic courses
- Beta-lactam allergies common
- Limited alternatives

**Management**
- Detailed history required
- Desensitization to needed antibiotics
- Consider home IV desensitization

### HIV

**Sulfonamide Allergy**
- 40-60% of HIV patients allergic
- TMP-SMX reactions
- Desensitization protocols available

**Immune Reconstitution**
- HAART may change drug tolerance
- Re-evaluate allergies after immune recovery

### Vancomycin

**Red Man Syndrome**
- Histamine-mediated, not IgE
- Flushing, pruritus, hypotension
- Rate-dependent

**True IgE-Mediated**
- Rare
- Anaphylaxis possible
- Desensitization protocols exist

**Management**

*Red Man Syndrome*
- Slower infusion
- Antihistamine premedication
- Not true allergy

*True IgE Reaction*
- Desensitization if vancomycin essential
- Use alternative antibiotics
      `
    },

    expert: {
      title: 'Expert-Level Drug Allergy Knowledge',
      description: 'Research frontiers and future directions',
      content: `
# Expert-Level Perspectives on Drug Allergy

## Immunologic Mechanisms in Depth

### Drug Haptenation and Presentation

**Hapten Concept**
- Small molecules (<1000 Da) not immunogenic alone
- Bind covalently to carrier proteins
- Create immunogenic hapten-carrier complex
- T-cell recognition of haptenated peptides

**Haptenation Pathways**
- Reactive metabolites
- Direct binding (some drugs)
- Protein adduct formation
- Antigen presentation by APCs

**p-I Concept (Pharmacologic Interaction)**
- Non-covalent drug-T-cell receptor interaction
- Direct TCR stimulation
- Explains immediate reactions without sensitization

### T-Cell Mediated Responses

**Drug-Specific T-Cells**
- CD4+ and CD8+ subsets
- Th1, Th2, Th17 phenotypes
- Cytotoxic T-cells in keratinocyte killing (SJS/TEN)

**HLA-Restricted Responses**
- Drug-HLA-T-cell interaction
- Specific HLA alleles predispose to SCARs
- HLA-B*57:01 → abacavir hypersensitivity
- HLA-B*15:02 → carbamazepine SJS/TEN

**Cytokine Milieu**
- IL-4, IL-5, IL-13 → eosinophilia
- IFN-γ, TNF-α → SJS/TEN
- IL-17 → neutrophil recruitment

### Genetic Susceptibility

**Pharmacogenomics**

*HLA Alleles and Drug Reactions*
| Drug | HLA Allele | Reaction |
|------|------------|----------|
| Abacavir | HLA-B*57:01 | SJS/TEN |
| Carbamazepine | HLA-B*15:02 | SJS/TEN (Asian) |
| Carbamazepine | HLA-A*31:01 | DRESS |
| Allopurinol | HLA-B*58:01 | SJS/TEN |
| Oxcarbazepine | HLA-B*15:02 | SJS/TEN |
| Phenytoin | HLA-B*15:02 | DRESS |

*Testing Recommendations*
- Abacavir: HLA-B*57:01 testing standard of care
- Carbamazepine: HLA-B*15:02 in Asian populations
- Allopurinol: HLA-B*58:01 in Han Chinese, Korean, Thai

**Enzyme Polymorphisms**
- Slow acetylators: DIL (drug-induced lupus)
- G6PD deficiency: Hemolysis with certain drugs
- Cytochrome P450 variants: Metabolism differences

## Diagnostic Innovation

### Advanced Testing Modalities

**Basophil Activation Test (BAT)**
- CD63 or CD203c upregulation
- Flow cytometry-based
- Useful for IgE-mediated reactions
- Predictive value improving

**Drug-Specific IgE**
- Commercial tests limited
- Penicillin testing available
- Need for more assays
- Component testing development

**ELISpot / Lymphocyte Proliferation**
- IFN-γ, IL-5 ELISpot
- Delayed reactions
- Research tool currently

**Intracellular Cytokine Staining**
- Drug-specific T-cell identification
- Flow cytometry panels
- Research applications

### Skin Testing Advances

**Non-Immediate Testing**
- Patch testing for delayed reactions
- Delayed intradermal reading (48-96 hours)
- Standardization efforts

**New Drug Testing**
- Biological agents
- Chemotherapy agents
- Non-standardized concentrations

## Novel Management Strategies

### Rapid Drug Desensitization

**Mechanisms**
- Mast cell desensitization
- Signal transduction inhibition
- Syk kinase inhibition
- Temporary tolerance

**Protocol Evolution**
- 4-step vs. 12-step protocols
- Weight-based vs. fixed dosing
- Outpatient protocols for lower-risk drugs
- Home desensitization (CF experience)

**Long-Term Outcomes**
- Tolerance persistence after stopping?
- Breakthrough reactions during therapy
- Reactions after temporary discontinuation

### Tolerance Induction

**Non-Desensitization Approaches**

*Co-Administration*
- Omalizumab with desensitization
- Anti-IL-5 for eosinophilic reactions
- Adjunct biologics under study

*Tolerance Protocols*
- Longer intervals between doses
- Lower maintenance doses
- Treatment of underlying mastocytosis

## Future Directions

### Biomarker Development

**Predictive Biomarkers**
- Pre-treatment genetic testing
- In vitro T-cell assays
- Serum biomarkers (tryptase, cytokines)

**Reaction Monitoring**
- Real-time biomarker assessment
- Point-of-care testing
- Smartphone applications

### Computational Approaches

**Molecular Modeling**
- Drug-protein binding prediction
- HLA-drug binding simulation
- Cross-reactivity prediction

**Artificial Intelligence**
- Reaction pattern recognition
- EHR-based allergy identification
- Clinical decision support

**Big Data Applications**
- Registry analyses
- Pharmacovigilance enhancement
- Population-level risk prediction

### Prevention Strategies

**Primary Prevention**
- HLA screening before high-risk drugs
- Pharmacogenomic testing
- Risk stratification

**Secondary Prevention**
- Accurate allergy documentation
- Electronic health record alerts
- Drug allergy de-labeling

**Tertiary Prevention**
- Desensitization protocols
- Alternative agent selection
- Patient education

## Controversies and Debates

### Penicillin Allergy De-labeling

**Barriers**
- Limited access to testing
- Time and resource constraints
- Provider reluctance
- Medicolegal concerns

**Strategies**
- Direct oral challenge (low-risk)
- Risk stratification algorithms
- Telemedicine approaches
- Penicillin allergy pathways

### Cross-Reactivity Uncertainties

**Beta-Lactam Cross-Reactivity**
- Side chain vs. beta-lactam ring
- Generational differences
- Individual patient variability
- Testing limitations

### Delabeling Frameworks

**Evidence-Based Approaches**
- Low-risk history: direct challenge
- Medium-risk: skin testing ± challenge
- High-risk: skin testing + challenge
- Shared decision-making

### Desensitization vs. Tolerance

**Terminology**
- "Desensitization": temporary tolerance
- "Tolerance": permanent state
- "Drug allergy resolution": natural history

**Clinical Implications**
- Patient education on temporary nature
- Need for repeat procedures
- Quality of life impact

## Global Perspectives

### Regional Drug Patterns

**Different Drugs, Different Problems**
- Genetic backgrounds influence reactions
- Local prescribing practices
- HLA allele prevalence variations
- Resource limitations

### Resource-Limited Settings

**Challenges**
- Limited testing availability
- Alternative drug access
- Desensitization capacity
- Training and expertise

**Innovative Solutions**
- Simplified protocols
- Telemedicine support
- Task-shifting to trained personnel

## Research Gaps

### Unanswered Questions
- What determines severity of reactions?
- How to predict who will develop tolerance?
- Optimal desensitization protocols for each drug?
- Long-term outcomes after delabeling?
- Biomarkers for diagnosis and prognosis?
- Prevention strategies for high-risk patients?
- Mechanisms of non-IgE reactions?
- Individual risk prediction?

### Emerging Areas
- Microbiome role in drug allergy
- Exosome biomarkers
- Novel desensitization approaches
- Gene therapy applications
- Nanoparticle delivery systems
      `
    }
  }
}
